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Toward a Better Understanding of...
Identifying Novel Therapeutic Targets in 
Myeloproliferative Neoplasms
Elisa De Togni
Mentor: Stephen Oh
A Myeloproliferative Neoplasm (MPN) is a clonal hematologic disorder in which red 
blood cells, platelets, or certain types of white blood cells are produced in excess by the 
bone marrow. Some MPNs can progress towards Acute Myeloid Leukemia (AML) in 
which the patient’s prognosis is extremely poor. Many MPNs have been linked with 
the presence of the JAK2V617F mutation or other lower frequency mutations in JAK2, 
CALR, and MPL which cause increased activity of JAK2, a non-receptor tyrosine kinase, 
leading to constitutive hyper-activation of the JAK-STAT signaling pathway. Recently, the 
emergence of JAK2 inhibitor therapy has benefited many patients with MPNs. However, 
not all of these patients respond to treatment with JAK2 inhibitors, indicating that other 
important signaling pathways may play a key role in the development of MPNs. In this 
ongoing study, Pevonedistat, a NEDD8-activating enzyme inhibitor is tested individually 
and in designed combinations with cytokines and other inhibitors to strategically target 
specific components of hyper-activated signal transduction pathways in order to promote 
apoptosis or suppress cellular proliferation. Cell viability assays are used to monitor the 
effects of Pevonedistat in cell lines that model growth and mutational characteristics of 
MPNs, such as Human Erythroleukemia (HEL) cells, a human mutant cell line of JAK2, 
and murine BaF3-MPL cells. Pevonedistat treatment of Myelofibrosis patient samples 
in colony forming unit (CFU) assays has shown promising results when compared to 
normal controls. Further testing will be performed on mice models with the ultimate 
goal of developing inhibitor therapies that may help to prevent the onset of AML and 
improve overall survival of patients.
